DMC Group LLC Has $273,000 Stock Position in Medtronic PLC $MDT

DMC Group LLC decreased its stake in shares of Medtronic PLC (NYSE:MDT) by 4.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,129 shares of the medical technology company’s stock after selling 148 shares during the quarter. DMC Group LLC’s holdings in Medtronic were worth $273,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Wedmont Private Capital increased its position in Medtronic by 26.1% during the first quarter. Wedmont Private Capital now owns 7,318 shares of the medical technology company’s stock worth $607,000 after buying an additional 1,516 shares during the last quarter. Capital Investment Advisors LLC increased its position in Medtronic by 6.2% during the first quarter. Capital Investment Advisors LLC now owns 9,770 shares of the medical technology company’s stock worth $878,000 after buying an additional 568 shares during the last quarter. City Holding Co. increased its holdings in shares of Medtronic by 2.1% during the 1st quarter. City Holding Co. now owns 11,107 shares of the medical technology company’s stock worth $998,000 after acquiring an additional 226 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Medtronic by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 61,052 shares of the medical technology company’s stock worth $5,402,000 after acquiring an additional 3,530 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. The Goldman Sachs Group decreased their target price on Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a report on Wednesday, October 1st. Wells Fargo & Company upped their price target on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Evercore ISI upped their target price on Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Saturday, September 27th. Finally, Daiwa Capital Markets upped their price objective on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $101.63.

Medtronic Trading Up 0.0%

Shares of NYSE:MDT opened at $98.44 on Wednesday. The company has a market capitalization of $126.27 billion, a P/E ratio of 27.12, a P/E/G ratio of 2.59 and a beta of 0.78. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The business’s 50 day simple moving average is $93.19 and its 200 day simple moving average is $88.59.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio is presently 78.24%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.